Skip to main content
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. — Investor Relations & Filings

Ticker · ZBIO ISIN · US98937L1052 US Manufacturing
Open in API
Filings indexed 147 across all filing types
Latest filing 2024-09-13 Director's Dealing
Country US United States of America
Listing US ZBIO

About Zenas BioPharma, Inc.

https://zenasbio.com/

Zenas BioPharma is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company is advancing a pipeline of immunology-based treatments to address significant unmet patient needs. Its two late-stage franchises are obexelimab and orelabrutinib. Obexelimab is an investigational bifunctional monoclonal antibody designed to suppress B cell activity by co-engaging CD19 and FcγRIIb. Orelabrutinib is an investigational, highly selective, CNS-penetrant oral small molecule BTK inhibitor. Zenas aims to become a global leader in providing innovative treatments for patients with autoimmune conditions.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-09-13 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-09-13 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the offering, incorporation by reference to a prior registration statement, consents from auditors and legal counsel, and signatures of company officers and directors. This type of filing is related to capital raising activities and financing. It is not an annual or quarterly report, audit report, earnings release, or any other category related to financial performance or governance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7402 characters) and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS.
2024-09-13 English
Regulatory Filings 2024
Regulatory Filings
2024-09-12 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It includes details about the registrant, the securities to be registered, and a signature page. The document does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing related to securities registration, which fits best under the category of Regulatory Filings (RNS). The document length is 3505 characters, which is relatively short and consistent with a regulatory filing form rather than a full report.
2024-09-10 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 for Zenas BioPharma, Inc. It is a request for acceleration of the effectiveness of the Registration Statement. The content is related to securities registration and underwriting, not a financial report or earnings release. The document length is short (1835 characters) and it is a formal regulatory communication. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-09-10 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.